IL101943D0 - Structure,production and use of heregulin - Google Patents

Structure,production and use of heregulin

Info

Publication number
IL101943D0
IL101943D0 IL10194392A IL10194392A IL101943D0 IL 101943 D0 IL101943 D0 IL 101943D0 IL 10194392 A IL10194392 A IL 10194392A IL 10194392 A IL10194392 A IL 10194392A IL 101943 D0 IL101943 D0 IL 101943D0
Authority
IL
Israel
Prior art keywords
heregulin
production
structure
use
Prior art date
Application number
IL10194392A
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US70525691A priority Critical
Priority to US76521291A priority
Priority to US79080191A priority
Priority to US07/847,743 priority patent/US5367060A/en
Priority to US88091792A priority
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL101943D0 publication Critical patent/IL101943D0/en

Links

IL10194392A 1991-05-24 1992-05-20 Structure,production and use of heregulin IL101943D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US70525691A true 1991-05-24 1991-05-24
US76521291A true 1991-09-25 1991-09-25
US79080191A true 1991-11-08 1991-11-08
US07/847,743 US5367060A (en) 1991-05-24 1992-03-06 Structure, production and use of heregulin
US88091792A true 1992-05-11 1992-05-11

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14490401A IL144904D0 (en) 1991-05-24 2001-08-14 Antibody directed against heregulin (hrg) polypeptides

Publications (1)

Publication Number Publication Date
IL101943D0 true IL101943D0 (en) 1992-12-30

Family

ID=27542108

Family Applications (4)

Application Number Title Priority Date Filing Date
IL10194392A IL101943D0 (en) 1991-05-24 1992-05-20 Structure,production and use of heregulin
IL12387298A IL123872D0 (en) 1991-05-24 1998-03-29 Isolated antibody binding to human heregulin (HRG) polypeptide
IL12387398A IL123873D0 (en) 1991-05-24 1998-03-29 Isolated heregulin protein a composition containing it and methods of obtaining it
IL14490401A IL144904D0 (en) 1991-05-24 2001-08-14 Antibody directed against heregulin (hrg) polypeptides

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL12387298A IL123872D0 (en) 1991-05-24 1998-03-29 Isolated antibody binding to human heregulin (HRG) polypeptide
IL12387398A IL123873D0 (en) 1991-05-24 1998-03-29 Isolated heregulin protein a composition containing it and methods of obtaining it
IL14490401A IL144904D0 (en) 1991-05-24 2001-08-14 Antibody directed against heregulin (hrg) polypeptides

Country Status (12)

Country Link
US (2) US5840525A (en)
EP (2) EP1114863A3 (en)
JP (1) JP3595552B2 (en)
AU (1) AU659863B2 (en)
CA (2) CA2108473C (en)
DE (2) DE69233137T2 (en)
DK (1) DK0586607T3 (en)
ES (1) ES2206448T3 (en)
IE (2) IE20010175A1 (en)
IL (4) IL101943D0 (en)
NZ (1) NZ242857A (en)
WO (1) WO1992020798A1 (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106666A1 (en) * 1991-04-10 2005-05-19 Cambridge Neuroscience Glial mitogenic factors, their preparation and use
US5716930A (en) * 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943D0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
JPH07506488A (en) * 1992-04-29 1995-07-20
AU693767B2 (en) * 1992-08-10 1998-07-09 Cambridge Neuroscience, Inc. Inhibitors of cell proliferation, their preparation and use
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
AU7042994A (en) * 1993-05-21 1994-12-20 Amgen, Inc. Recombinant (neu) differentiation factors
CN1111910A (en) * 1993-07-06 1995-11-15 霍夫曼-拉罗奇有限公司 Mammamodulin, a hormone-independent mammary tumor cells specific protein
US5518885A (en) * 1994-04-19 1996-05-21 The United States Of America As Represented By The Department Of Health & Human Services ERBB2 promoter binding protein in neoplastic disease
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
AUPM959894A0 (en) * 1994-11-22 1994-12-15 Crc For Biopharmaceutical Research Pty Ltd Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5912326A (en) * 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
DE69732711T2 (en) 1996-07-12 2006-03-16 Genentech, Inc., South San Francisco Gamma-heregulin
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
DE69840699D1 (en) 1997-02-10 2009-05-14 Genentech Inc heregulin variants
EP1007630B1 (en) * 1997-04-30 2006-04-19 Hans Klingemann Natural killer cell lines and methods of use
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
US6080845A (en) * 1998-08-05 2000-06-27 Amgen Inc. Monoclonal antibody against utricular epithelium
US6017886A (en) * 1998-08-05 2000-01-25 Amgen Inc. Use of NDF peptide as growth factor for sensory epithelium
JP2003530816A (en) * 1998-09-28 2003-10-21 カイロン コーポレイション Human genes and gene expression products
AU764037B2 (en) * 1998-11-07 2003-08-07 Genentech Inc. Method for enhancing proliferation of inner ear hair cells using ligands for HER2 and/or HER3 receptors
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
WO2000053813A1 (en) * 1999-03-11 2000-09-14 Massachusetts Institute Of Technology Pangenomic libraries
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
SI2803367T1 (en) 1999-06-25 2018-04-30 Immunogen, Inc. Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
BR0012195A (en) * 1999-06-25 2002-07-23 Genentech Inc Method for treating prostate cancer in a human, article of manufacture and the use of an antibody which binds ErbB2
RU2270029C2 (en) 1999-06-25 2006-02-20 Джинентех, Инк. HUMANIZED ANTIBODY THAT SHOWS CAPACITY TO BIND ErbB2 AND BLOCK ACTIVATION OF ErbB2 RECEPTOR BY LIGAND (VARIANTS) AND COMPOSITION FOR USING IN CANCER TREATMENT COMPRISING THIS ANTIBODY
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20020034772A1 (en) * 1999-06-29 2002-03-21 Orlow Seth J. Methods and compositions that affect melanogenesis
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
JP4658423B2 (en) * 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Polypeptides and polynucleotides to enhance the immune response against Her-2 protein
KR20090024308A (en) * 1999-08-27 2009-03-06 제넨테크, 인크. Dosages for treatment with anti-erbb2 antibodies
USRE43899E1 (en) 1999-10-01 2013-01-01 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2399452A1 (en) 2000-02-11 2001-08-16 Proteosys Ag Use of neuregulin-.beta. as an indicator and/or target
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US20040052793A1 (en) * 2001-02-22 2004-03-18 Carter Paul J. Caspase activivated prodrugs therapy
AU783679B2 (en) * 2000-02-24 2005-11-24 Genentech Inc. Caspase activated prodrugs therapy
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
HU0300369A2 (en) 2000-04-11 2003-06-28 Genentech, Inc. Multivalent antibodies and their applications
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US20030017491A1 (en) * 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
EP2418218A1 (en) 2001-08-06 2012-02-15 ProteoSys AG Neuregulin-Beta isoforms associated with neuronal processes
DE10210427A1 (en) 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Human monoclonal antibodies
WO2003087131A2 (en) 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
JP2006504406A (en) 2002-06-28 2006-02-09 セントカー・インコーポレーテツド Mammalian ch1 deleted mimetibody, compositions, methods and uses
WO2004005351A2 (en) 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
PT1585966E (en) * 2002-07-15 2012-02-20 F.Hoffmann-La Roche Ag, Treatment of cancer with the anti-erbb2 antibody rhumab 2c4
EP1572972A4 (en) * 2002-11-21 2007-11-21 Genentech Inc Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1742969A2 (en) 2003-11-12 2007-01-17 OncoMab GmbH Methods of identifying neoplasm-specific antibodies and uses thereof
WO2005099756A2 (en) * 2004-04-08 2005-10-27 Agus David B ErbB ANTAGONISTS FOR PAIN THERAPY
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
GT200500155A (en) * 2004-06-16 2006-05-15 Therapy resistant cancer platinum
MX2007000723A (en) 2004-07-22 2007-03-12 Genentch Inc Her2 antibody composition.
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
JP2008523073A (en) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッドGenentech,Inc. Selection of patients for treatment with Her inhibitors
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
CA2595395A1 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
EP1912680B1 (en) * 2005-06-15 2014-11-26 The Ohio State University Research Foundation Her-2 peptides
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2634974A1 (en) * 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for improved cardiac function
ES2661952T3 (en) 2006-08-04 2018-04-04 Medimmune Limited human antibodies against ERBB2
BRPI0808418A2 (en) 2007-03-02 2014-07-22 Genentech Inc Prediction of response to a HER inhibitor
BRPI0809435A2 (en) 2007-03-27 2014-09-09 Sea Lane Biotechnologies Llc Constructs and libraries comprising light chain sequences of antibodies substituted
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
RU2491955C2 (en) 2007-11-16 2013-09-10 МЕН-ЭнЭрЖ СА Active soluble isoforms of neuregulin, which carry post-translation modifications
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
CN104447995A (en) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
WO2010132604A2 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
JP5705836B2 (en) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Modulators for her2 signaling gastric cancer patients expressing Her2
WO2011103242A1 (en) 2010-02-18 2011-08-25 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
CN103959065B (en) 2011-10-06 2018-07-17 Aveo制药公司 Predict tumor response of antibodies against erbb3
US20130195870A1 (en) 2011-11-30 2013-08-01 Genentech, Inc. ERBB3 Mutations In Cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
CA2859744A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
BR112015012644A2 (en) 2012-11-30 2017-12-19 Hoffmann La Roche Method for determining the need for a patient with cancer, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit;
MX2016005854A (en) 2013-11-07 2017-07-28 Inserm (Institut Nat De La Santé Et De La Rech Médicale) Neuregulin allosteric anti-her3 antibody.
CA2930307A1 (en) 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
KR20180010259A (en) 2015-05-30 2018-01-30 몰레큘러 템플레이츠, 인코퍼레이션. De-immunization of a Shiga toxin subunit scaffold and cells comprising the same-targeting molecules
CN106729743A (en) 2015-11-23 2017-05-31 四川科伦博泰生物医药股份有限公司 Anti-ErbB2 antibody-drug conjugate, composition, preparation method and application of anti-ErbB2 antibody-drug conjugate
CN107589261B (en) * 2017-09-08 2019-02-22 上海宝藤生物医药科技股份有限公司 It is a kind of for detecting the kit of breast cancer
CN107589262B (en) * 2017-09-08 2019-02-22 枫木年轮生物科技(广州)有限公司 For detecting the kit of breast cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882275A (en) * 1984-02-29 1989-11-21 The Children's Medical Center Corporation Method of purifying endothelial cell growth factors using immobilized heparin
US4683195B1 (en) * 1986-01-30 1990-11-27 Cetus Corp
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
DE69126430D1 (en) * 1990-04-06 1997-07-10 Univ Pennsylvania Ligand for the neu gene-product
CA2083688A1 (en) * 1990-05-25 1991-11-26 Marc Lippman Growth factor which inhibits the growth of cells overexpressing the human oncogene erbb-2
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
FR2664086B1 (en) * 1990-07-02 1994-08-19 Centre Nat Rech Scient
NZ241292A (en) * 1991-01-14 1994-04-27 Univ Georgetown Ligands for the erbb-2 transmembrane protein and pharmaceutical compositions thereof
NZ242000A (en) * 1991-03-17 1994-03-25 Yeda Res & Dev Purified mammalian proteinaceous factor which stimulates neu receptor
US5169837A (en) * 1991-03-28 1992-12-08 Allelix Biopharmaceuticals Inc. Isolated osteogenic factor
GB9107566D0 (en) * 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
IL101943D0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5237056A (en) * 1991-05-29 1993-08-17 President And Fellows Of Harvard College DNA encoding a protein which copurifies with acetylcholine receptor inducing activity and uses therefor
JPH07506488A (en) * 1992-04-29 1995-07-20
DE69328091D1 (en) * 1992-04-29 2000-04-20 Georgetown University Washingt Binding peptides for interaction with growth factors as ligands of the receptor of the epidermiswachstumsfactor and the erbB-2 receptor
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use

Also Published As

Publication number Publication date
AU659863B2 (en) 1995-06-01
CA2108473A1 (en) 1992-11-25
EP1114863A2 (en) 2001-07-11
IE921654A1 (en) 1992-12-02
DK0586607T3 (en) 2003-11-17
ES2206448T3 (en) 2004-05-16
US5840525A (en) 1998-11-24
EP1114863A3 (en) 2004-06-09
WO1992020798A1 (en) 1992-11-26
NZ242857A (en) 1993-08-26
IL144904D0 (en) 2002-06-30
CA2331239A1 (en) 1992-11-25
CA2108473C (en) 2009-01-20
IE20010175A1 (en) 2003-03-05
AU2347492A (en) 1992-12-30
DE69233137D1 (en) 2003-08-28
JPH06508031A (en) 1994-09-14
DE69233137T2 (en) 2004-04-29
IL123872D0 (en) 1998-10-30
US5641869A (en) 1997-06-24
EP0586607A1 (en) 1994-03-16
EP0586607B1 (en) 2003-07-23
IL123873D0 (en) 1998-10-30
JP3595552B2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
AU587863B2 (en) Vitamin-containing granules and production thereof
DE3572485D1 (en) Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
GB2200115B (en) Novel peptide derivatives, their production and use
AU671595B2 (en) Production of polyalkanoate
AU679021B2 (en) N-heteroaryl-N'-phenylurea derivatives, their production and use
JPS63233941A (en) Polyacetal, manufacture and use
HUT67020A (en) Compact, antibacterial preparations with granular structure and process for production of them
DE3574379D1 (en) Tetrahydrophtalimides, and their production and use
IL95975D0 (en) Benzimidazole derivatives,their production and use
AU1108695A (en) Aza-4-iminoquinolines, methods of preparing them and their use
AU2383192A (en) Method of making curved, shaped absorbent article
AU644008B2 (en) Beta-lactam compounds, and their production and use
HU9501329D0 (en) Novel 3,3-diphenylpropylamines, their use and preparation
ZA9407799B (en) Inhibition of cytokine production
IL89885D0 (en) Fibrin-collagen tissue equivalents and their production
HU913507D0 (en) Suspendable preparation and process for its production
IL97890D0 (en) Production of sucrose-6-esters
HK1004481A1 (en) Depsipeptide derivative, production thereof and use thereof
IL74305A (en) N-aryl-3-aryl-4,5-dihydro-1h-pyrazole-1-carboxamides,their production and their use as insecticides
HK1027360A1 (en) Production of recombinant human lactofferrin.
AU4198793A (en) Microparticle preparation and production thereof
GR3026697T3 (en) Imide derivatives, and their production and use
NZ244392A (en) Glial derived neurotrophic factor, its production and use
SG70980A1 (en) Novel 4-arylpiperazines and 4-arylpiperidines
GR3017981T3 (en) Aminocoumaran derivatives, their production and use.

Legal Events

Date Code Title Description
KB Patents renewed
KB Patents renewed
EXP Patent expired